ACADIA Pharmaceuticals (ACAD, Financial) has received a positive update from analyst Ami Fadia at Needham. The firm has maintained its "Buy" rating while raising its price target from $27.00 to $30.00. This adjustment reflects an increase of 11.11% in the price target.
The change comes as a strategic move by Needham to reflect the potential growth and performance outlook for ACADIA Pharmaceuticals. With the maintained "Buy" rating, the analyst's update suggests continued confidence in ACAD (ACAD, Financial)'s market position and future prospects.
ACADIA Pharmaceuticals (ACAD, Financial) investors can view this raised price target and maintained rating as an encouraging sign, indicating potential upside in the stock. The information was released on May 19, 2025, aligning with Needham's ongoing analysis and evaluation of the company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for ACADIA Pharmaceuticals Inc (ACAD, Financial) is $23.75 with a high estimate of $37.00 and a low estimate of $11.00. The average target implies an upside of 6.69% from the current price of $22.26. More detailed estimate data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, ACADIA Pharmaceuticals Inc's (ACAD, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ACADIA Pharmaceuticals Inc (ACAD, Financial) in one year is $34.10, suggesting a upside of 53.19% from the current price of $22.26. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Summary page.
